secwatch.observer — SEC 8-K summary
======================================

Issuer:     GridAI Technologies Corp. (GRDX)
CIK:        0001604191
Form:       8-K
Filed at:   2023-09-14T23:59:59+00:00
Accession:  0001104659-23-100614
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

First Wave BioPharma licenses Capeserod from Sanofi; $500k upfront, up to $281M milestones, royalties
--------------------------------------------------------------------------------

- Exclusive global license from Sanofi for Capeserod, a 5-HT4 partial agonist, to develop for GI indications.
- Upfront payment of $500k; up to $46M in development/regulatory milestones and up to $235M in commercial milestones.
- Sanofi eligible for mid-to-high single-digit royalties on net sales and percentage of sublicense revenue.
- Sanofi has right of first refusal to reacquire Capeserod after certain clinical stages.
- First Wave plans to initiate Phase 2 trials in 2024 after FDA meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604191/000110465923100614/0001104659-23-100614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604191/000110465923100614/tm2326019d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-100614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer